期刊
FRONTIERS IN ONCOLOGY
卷 9, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2019.00080
关键词
cancer; uPAR; CRISPR/Cas9; malignancy; drug resistance
类别
资金
- National Key Research and Development Program of China [2017YFA0505104]
- National Natural Science Foundation of China [81772540]
- Guangdong Natural Science Funds for Distinguished Young Scholar [2014A030306001]
- Guangdong Special Support Program for Young Talent [2015TQ01R350]
- Science and Technology Program of Guangdong [2016A050502027]
- Science and Technology Program of Guangzhou [201704030058]
Urokinase plasminogen activator receptor (uPAR), a member of the lymphocyte antigen 6 protein superfamily, is overexpressed in different types of cancers and plays an important role in tumorigenesis and development. In this study, we successfully targeted uPAR by CRISPR/Cas9 system in two human cancer cell lines with two individual sgRNAs. Knockout of uPAR inhibited cell proliferation, migration and invasion. Furthermore, knockout of uPAR decreases resistance to 5-FU, cisplatin, docetaxel, and doxorubicin in these cells. Although there are several limitations in the application of CRISPR/Cas9 system for cancer patients, our study offers valuable evidences for the role of uPAR in cancer malignancy and drug resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据